Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sepetaprost - Santen Pharmaceutical

Drug Profile

Sepetaprost - Santen Pharmaceutical

Alternative Names: DE 126; ONO 9054; STN-10126; STN-1012600

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ono Pharmaceutical
  • Developer Ono Pharmaceutical; Santen Pharmaceutical
  • Class Antiglaucomas; Oxepins; Prostaglandins
  • Mechanism of Action Prostaglandin E EP3 receptor agonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ocular hypertension; Open-angle glaucoma

Most Recent Events

  • 21 Jun 2023 Company completes a phase I pharmacokinetic trial (In volunteers, In adults) in Japan (Ophthalmic) (NCT05905653)
  • 25 May 2023 Santen Pharmaceutical initiates a phase I pharmacokinetic trial (In volunteers, In adults) in Japan (Ophthalmic) (NCT05905653)
  • 18 Apr 2023 Santen Pharmaceutical completes a phase III trial for Open-angle glaucoma in Japan (Ophthalmic) (NCT05495061)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top